- Home
- CMMB vs PAVM Comparison
CMMB vs PAVM Comparison
Compare CMMB & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | PAVM |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Israel | United States |
| Employees | N/A | 107 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMMB | PAVM |
|---|---|---|
| Price | $1.86 | $10.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $25.00 | ★ $510.00 |
| AVG Volume (30 Days) | ★ 73.0K | 28.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.56 |
| P/E Ratio | $45.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.21 |
| 52 Week High | $3.86 | $28.44 |
Technical Indicators
Market Signals| Indicator | CMMB | PAVM |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 52.12 |
| Support Level | $1.48 | $0.38 |
| Resistance Level | $1.85 | $10.98 |
| Average True Range (ATR) | 0.19 | 0.70 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 61.26 | 55.09 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.